Plasmid DNA are circular DNA molecules that are independent of chromosomal DNA and can replicate autonomously. Plasmid DNA is used commonly for gene delivery in various gene therapy and DNA vaccination applications due to its ability to carry foreign genes and have them expressed in host organisms. Gene therapy is an emerging field that aims to treat diseases by replacing, manipulating or supplementing non-functional genes. Advancements in gene therapy using plasmid DNA has boosted the demand for plasmid DNA for preclinical and clinical research.
The global plasmid DNA manufacturing market is estimated to be valued at US$ 1038.19 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period from 2024 to 2031.
Key Takeaways
Key players: Key players operating in the plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.
Key players operating in the Plasmid DNA Manufacturing Market Trends are focusing on increasing their plasmid DNA manufacturing capacity to meet the growing demand for gene therapies. For instance, Aldevron expanded its DNA production facilities to add 24,000 square feet of GMP production space for plasmid DNA.
Growing demand: Advancements in gene therapy research for various diseases like cancer, genetic disorders, infectious diseases has increased the demand for high-quality and GMP grade plasmid DNA. Several gene therapy clinical trials are ongoing which requires plasmid DNA manufacturing at a large scale.
Global expansion: Major players are undertaking strategic initiatives such as acquisitions, partnerships and expanding manufacturing facilities globally to strengthen their plasmid DNA manufacturing and supply capabilities internationally especially in emerging markets. For instance, Cobra Biologics established a new gene therapy manufacturing facility in Germany.
Market key trends
One of the Plasmid DNA Manufacturing Market Size And Trends manufacturing market is the automation and continuous manufacturing technologies. Advanced automation and continuous manufacturing allows for higher yields and reproducibility of plasmid DNA production. This helps plasmid DNA manufacturers to rapidly scale-up production according to demand. Technologies like continuous counter current chromatography are being explored for plasmid DNA purification to enhance efficiency and lower costs.
Porter's Analysis
Threat of new entrants: Low capital requirements and readily available expertise in DNA synthesis pose low barriers for new entrants in the plasmid DNA manufacturing market. However, incumbents have established relationships with regulators and customers.
Bargaining power of buyers: There exists numerous manufacturers in the market. Buyers can negotiate on price and demand customized solutions. Quality standards and regulatory requirements also allow some bargaining power to buyers.
Bargaining power of suppliers: Suppliers of raw materials like enzymes have some bargaining power due to differentiated products and formulations. However, availability of substitutes limits their power.
Threat of new substitutes: New technologies like gene editing provide alternatives to plasmid DNA for transfection. However, high specificity and versatility of plasmids restrict impact of substitutes in short term.
Competitive rivalry: Presence of many mid-sized players intensifies competition. Industry is moving towards consolidation. Competitive parameters include quality, pricing, customization and intellectual property.
Geographical Regions
North America accounts for the largest share of the plasmid DNA manufacturing market, primarily due to presence of key market players and rapid adoption of cell and gene therapies. The US contributes majority of the North American market value.
Asia Pacific region is poised to witness highest growth during the forecast period majorly owing to expansion activities by various players and increasing R&D investments by governments in countries like China and India for development of indigenous plasmid DNA manufacturing capabilities.
Get More Insights On, Plasmid DNA Manufacturing Market
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment